ROR1 and triple-negative breast carcinoma: In parallel with these pre-clinical developments, a clinical trial of ROR1-targeted CAR T-cells in patients with NSCLC and triple-negative breast cancer (TNBC) was initiated at the Fred Hutchinson Cancer Center (NCT02706392) [49].